

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

02 MAR 05 PM 2:51

1. Registrant Name <u>Genzyme Corporation</u>			
2. Address <input type="checkbox"/> Check if different than previously reported <u>1020 Nineteenth Street, NW, Suite 550, Washington, DC 20036</u>			
3. Principal Place of Business (if different from line 2) City: <u>Cambridge</u> State/Zip (or Country) <u>MA 01239</u>			
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
<u>Mary McGrane</u>	<u>(202) 296-3280</u>		<u>16054-12</u>
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID #
			<u>30257000</u>

TYPE OF REPORT 8. Year 2001 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report → Termination Date _____

11. No Lobbying Activities

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Income (nearest \$20,000)	\$10,000 or more <input type="checkbox"/> ⇒ \$ <u>540,000.00</u> Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of method.
	<input type="checkbox"/> Method A. Reporting amounts using LDA definition
	<input type="checkbox"/> Method B. Reporting amounts under section 6033(c) Internal Revenue Code
	<input checked="" type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code

Signature _____

Printed Name and Title Mary McGrane, Senior Vice President, Government Relations



Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

- a. Federal oversight and regulation of gene therapy research and Protection of human research subjects
- b. S. 1379 – “Rare Diseases Act of 2001”

17. House(s) of Congress and Federal agencies contacted Check if None

- a. United States Senate
United States House of Representatives
Executive Office of the President
Department of Health and Human Services
- b. United States Senate
United States House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Lisa J. Raines		<input type="checkbox"/>
Mary McGrane		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each such foreign entity in the specific issues listed on line 16 above Check if None

Signature _____

Date: 11 February 20

Printed Name and Titles Mary McGrane, Senior Vice President, Government Relations



Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the reg: engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** p information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

- Support expansion of the orphan drug tax credit
 - S. 1052 - "Bipartisan Patient Protection Act"
 - H.R. 1298/S. 1341 - "The Orphan Drug Tax Credit Act of 2001"
 - H.R. 1836 - "Economic Growth and Tax Relief Reconciliation Act of 2001"
 - H.R. 2563 - "Bipartisan Patient Protection Act"

17. House(s) of Congress and Federal agencies contacted Check if None

United States Senate
United States House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Lisa J. Raines		<input type="checkbox"/>
Mary McGrane		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each such foreign entity in the specific issues listed on line 16 above Check if None

Signature _____

Date: 11 February 20

Printed Name and Titles Mary McGrane, Senior Vice President, Government Relations



Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

a) Support Medicare coverage of oral phosphate-binding drugs

H.R. 3246 – “To amend title XVIII of the Social Security Act to provide for coverage under the Medicare Program of **oral** drugs to reduce serum **phosphate** levels in patients with end-stage renal disease.”
S. 1304 – “A bill to amend title XVIII of the Social Security Act to provide for coverage under the Medicare program of **oral** drugs to reduce serum **phosphate** levels in dialysis patients with end-stage renal disease.”

b) Medicare Prescription Drug Benefit:

S. 10 - “Medicare Prescription Drug Coverage Act of 2001”
S. 357 - “Medicare Preservation and Improvement Act of 2001”
S. 358 - “Medicare Prescription Drug and Modernization Act of 2001”
S. 1135 - “Medicare Reform Act of 2001”

c) Support modification of Medicare hospital Prospective payment system for hospital outpatient department

d) Medicare payment system for physician-administered drugs

17. House(s) of Congress and Federal agencies contacted Check if None

- a) United States Senate
United States House of Representatives
- b) United States Senate
United States House of Representatives
Executive Office of the President
Department of Health and Human Services
- c) United States Senate
United States House of Representatives
Department of Health and Human Services
- d) United States Senate
United States House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Lisa J. Raines		<input type="checkbox"/>
Mary McGrane		<input type="checkbox"/>

19. Interest of each such foreign entity in the specific issues listed on line 16 above Check if None

Signature _____

Date: 11 February 2001

Printed Name and Titles Mary McGrane, Senior Vice President, Government Relations



Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the regi engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code INS (one per page)

16. Specific lobbying issues

Support provisions prohibiting health plans from labeling FDA approved products as “experimental” or “investigational”:

- H.R. 526 – “Bipartisan Patient Protection Act of 2001” – Section 118(b)
- H.R. 2563 – “Bipartisan Patient Protection Act of 2001” – Section 118(b)
- S. 283 – “Bipartisan Patient Protection Act of 2001” - Section 118(b)
- S. 872 – “Bipartisan Patient Protection Act of 2001” – Section 118(b)
- S. 1052 – “Bipartisan Patient Protection Act of 2001” – Section 118(b)

17. House(s) of Congress and Federal agencies contacted Check if None

United States Senate
United States House of Representatives
Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Lisa J. Raines		<input type="checkbox"/>
Mary McGrane		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each such foreign entity in the specific issues listed on line16 above Check if None

Signature _____

Date: 11 February 2002

Printed Name and Titles Mary McGrane, Senior Vice President, Government Relations



Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

Oppose creation of a system to approve generic biologics

S. 812 – “Greater Access to Affordable Pharmaceuticals Act of 2001”

H.R. 1862 - “Greater Access to Affordable Pharmaceuticals Act of 2001”

H.R. 2830 – “The Agriculture, Rural Development, Food and Drug Administration (FDA) and Related Agency Appropriations Act of 2002”

17. House(s) of Congress and Federal agencies contacted

Check if None

United States Senate

United States House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Lisa J. Raines		<input type="checkbox"/>
Mary McGrane		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each such foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____

Date: 11 February 20

Printed Name and Titles Mary McGrane, Senior Vice President, Government Relations



Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the regis engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code, pr information as requested. Attach additional page(s) as needed.**

15. General issue area code HCR (one per page)

17. Specific lobbying issues

Renewal of Prescription Drug User Fee Act

17. House(s) of Congress and Federal agencies contacted

Check if None

Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Lisa J. Raines		<input type="checkbox"/>
Mary McGrane		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each such foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____

Date: 11 February 20

Printed Name and Titles Mary McGrane, Senior Vice President, Government Relations



Registrant Name Genzyme Corporation Client Name _____

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City

State/Zip (or Country)

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

Lisa Raines

ISSUE UPDATE

24. General lobbying issues previously reported that no longer pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	C p c

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant affiliated organization

Signature



Date 11 February 2002

Printed Name and Title Mary McGrane, Senior Vice President, Government Relations

Form LD-2 (Rev. 6/98)

Page 8

